Quest Diagnostics Q3 revenue $2.82B (+13.1%), raises FY2025 adjusted EPS guidance to $9.76–$9.84

QUEST DIAGNOSTICS INC

2025-Q3 EPS reported $6.57 revenue$8,229,000,000

Q3 reported diluted EPS $2.16 (+8.5%); adjusted diluted EPS $2.60 (+13.0%) vs $2.30 prior year.
Revenue up 13.1% to $2.82B with 6.8% organic growth; diagnostic info services revenue $2.76B.
FY2025 adjusted EPS guidance raised to $9.76–$9.84 from $9.63–$9.83; revenue guidance raised to $10.96B–$11.00B.
Year-to-date cash from operations $1.42B, up 63.1%; Co-Lab Solutions annual revenue run-rate ~$1B expected next year.
Announced lab services JV with Corewell Health; acquired dialysis testing assets from Fresenius Medical Care.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.